Guo Mingxin, Fang Wentong, Hu Zhiqiang
Department of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China.
Department of pharmacy, Jiangsu Province Hospital, Nanjing, China.
Front Immunol. 2024 Nov 26;15:1429483. doi: 10.3389/fimmu.2024.1429483. eCollection 2024.
Immunotherapy has become a global focus in cancer treatment and research, with promising results from targeting immune checkpoints in tumors like non-small cell lung cancer, colon cancer, and melanoma. However, resistance to immune checkpoint inhibitors (ICIs) remains a significant challenge. Traditional Chinese medicine (TCM), known for its low toxicity and minimal side effects, shows promise in enhancing cancer treatment when combined with modern therapies. This study reviews recent research on ICIs resistance mechanisms and highlights TCM's potential in overcoming this resistance, aiming to improve ICIs efficacy while minimizing toxicity.
免疫疗法已成为癌症治疗和研究的全球焦点,在针对非小细胞肺癌、结肠癌和黑色素瘤等肿瘤中的免疫检查点方面取得了有前景的成果。然而,对免疫检查点抑制剂(ICI)的耐药性仍然是一个重大挑战。以低毒性和最小副作用著称的传统中药,在与现代疗法联合使用时,显示出增强癌症治疗效果的潜力。本研究回顾了最近关于ICI耐药机制的研究,并强调了中药在克服这种耐药性方面的潜力,旨在提高ICI的疗效,同时将毒性降至最低。